A Phase 1 interventional study of Pirtobrutinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach. The study will also evaluate the safety and tolerability of pirtobrutinib (LOXO-305). Participants will stay in this study for up to 53 days (screening through follow-up call).
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 200 milligrams (mg) of pirtobrutinib administered in the morning on Day 1, under fasted conditions (Treatment A) followed by 200 mg pirtobrutinib administered orally in the morning on Day 8, under fed condition (Treatment B). A washout period of 7 days was maintained between Treatments A and B.
Drug: Pirtobrutinib
Participants received a single oral dose of 200 mg pirtobrutinib administered in the morning on Day 1, under fed conditions (Treatment B) followed by 200 mg of pirtobrutinib administered orally in the morning on Day 8, under fasted conditions (Treatment A). A washout period of 7 days was maintained between Treatments A and B.
Drug: Pirtobrutinib
Administered orally.
Also known as: LOXO-305, LY3527727
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
PK: AUC0-24 of pirtobrutinib was reported.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 1 and 8
PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib
PK: AUC0-t of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib
PK: AUC0-inf of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib
PK: %AUCextrap of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
PK: CL/F of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib
PK: t½ of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib
PK: Cmax of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib
PK: Tmax of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Apparent Terminal Elimination Rate Constant (Lambda Z) of Pirtobrutinib
PK: Lambda Z of pirtobrutinib was reported.
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib
PK: Vz/F of pirtobrutinib was reported
Time frame: Pre-dose 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose on Days 1 and 8
| Milestone | 200 mg Pirtobrutinib: Treatment AB | 200 mg Pirtobrutinib: Treatment BA |
|---|---|---|
| Started | 10 | 10 |
| Received at least 1 dose of study drug | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
PK: AUC0-24 of pirtobrutinib was reported.
| hour nanogram per milliliter (h*ng/mL) | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib | 51700 ± 18.7 | 45500 ± 42.0 |
PK: AUC0-t of pirtobrutinib was reported.
| h*ng/mL | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib | 83900 ± 25.1 | 77800 ± 48.9 |
PK: AUC0-inf of pirtobrutinib was reported.
| h*ng/mL | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Area Under the Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Pirtobrutinib | 85100 ± 25.0 | 79000 ± 48.3 |
PK: %AUCextrap of pirtobrutinib was reported.
| percentage of AUCextrap | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Percentage Extrapolation for AUC0-inf (%AUCextrap) of Pirtobrutinib | 1.21 ± 43.7 | 1.25 ± 65.1 |
PK: CL/F of pirtobrutinib was reported.
| liter per hour (L/h) | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib | 2.35 ± 25.0 | 2.53 ± 48.3 |
PK: t½ of pirtobrutinib was reported.
| hour | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Apparent Plasma Terminal Elimination Half-life (t½) of Pirtobrutinib | 18.4 ± 22.2 | 19.2 ± 25.4 |
PK: Cmax of pirtobrutinib was reported.
| nanogram per milliliter (ng/mL) | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Maximum Observed Concentration (Cmax) of Pirtobrutinib | 4200 ± 18.6 | 3250 ± 35.9 |
PK: Tmax of pirtobrutinib was reported.
| hour | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib | 3.00 (1.50 to 4.05) | 4.00 (2.50 to 8.00) |
PK: Lambda Z of pirtobrutinib was reported.
| 1/hour (1/h) | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| Subject 1 | 0.0199 | 0.0155 |
| Subject 2 | 0.0355 | 0.0363 |
| Subject 3 | 0.0308 | 0.0303 |
| Subject 4 | 0.0457 | 0.0436 |
| Subject 5 | 0.0473 | 0.0352 |
| Subject 6 | 0.0333 | 0.0307 |
| Subject 7 | 0.0394 | 0.0381 |
| Subject 8 | 0.0427 | 0.0459 |
| Subject 9 | 0.0404 | 0.0395 |
| Subject 10 | 0.0315 | 0.0365 |
| Subject 11 | 0.0554 | 0.0513 |
| Subject 12 | 0.0302 | 0.0344 |
| Subject 13 | 0.0331 | 0.0265 |
| Subject 14 | 0.0362 | 0.0383 |
| Subject 15 | 0.0382 | 0.0396 |
| Subject 16 | 0.0466 | 0.0381 |
| Subject 17 | 0.0392 | 0.0440 |
| Subject 18 | 0.0432 | 0.0418 |
| Subject 19 | 0.0408 | 0.0397 |
| Subject 20 | 0.0408 | 0.0360 |
PK: Vz/F of pirtobrutinib was reported
| liter | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| PK: Apparent Volume of Distribution at the Terminal Phase (Vz/F) of Pirtobrutinib | 62.5 ± 21.2 | 70.1 ± 43.4 |
Collected over Baseline to end of follow-up (up to 24 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Pirtobrutinib (Fasted) | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| 200 mg Pirtobrutinib (Fed) | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Event | 200 mg Pirtobrutinib (Fasted) | 200 mg Pirtobrutinib (Fed) |
|---|---|---|
| DizzinessNervous system disorders | 1/20 | 0/20 |
| DysgeusiaNervous system disorders | 1/20 | 0/20 |
| HeadacheNervous system disorders | 0/20 | 1/20 |
| DiarrhoeaGastrointestinal disorders | 0/20 | 1/20 |
| Dry mouthGastrointestinal disorders | 0/20 | 1/20 |
| PetechiaeSkin and subcutaneous tissue disorders | 1/20 | 0/20 |
All participants who received at least 1 dose of Pirtobrutinib.
| Age, Continuous(years) | 200 mg Pirtobrutinib: Treatment AB | 200 mg Pirtobrutinib: Treatment BA | Total |
|---|---|---|---|
| Mean | 35.9 ± 10.10 | 35.9 ± 11.10 | 35.9 ± 10.33 |
| Sex: Female, Male(Participants) | 200 mg Pirtobrutinib: Treatment AB | 200 mg Pirtobrutinib: Treatment BA | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 8 | 8 | 16 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Pirtobrutinib: Treatment AB | 200 mg Pirtobrutinib: Treatment BA | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 7 | 13 |
| Not Hispanic or Latino | 4 | 3 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 200 mg Pirtobrutinib: Treatment AB | 200 mg Pirtobrutinib: Treatment BA | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 6 | 8 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 200 mg Pirtobrutinib: Treatment AB | 200 mg Pirtobrutinib: Treatment BA | Total |
|---|---|---|---|
| United States | 10 | 10 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Mar 2021, 2 months.
Results were first posted in Mar 2025, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib